CDC research opportunity
Executive Summary
Centers for Diseases Control & Prevention calls for collaborators to enter into a Cooperative Research & Development Agreement to develop, refine and validate "three interrelated technologies: (1) the exchangeable template reaction, a method to assemble synthetic genes; (2) the construction of hepatitis C virus specific 'mosaic' proteins composed of immunodominant antigenic epitopes; and (3) differential HCV diagnostic tests," CDC says in July 6 Federal Register notice. The CRADA partner will be responsible for preparing "all synthetic peptides and oligonucleotides as necessary for each project area" and "monospecific and monoclonal antibodies whenever appropriate," as well as purifying "antigens from recombinant lysates as needed"
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth